Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone suggests a neutral to mildly positive view of the article, with discussions including mentions of barriers and facilitators in treatment strategies, like 'measuring disease activity' and 'doctor-patient relationships,' indicating recognition of the study’s relevance. Words like 'review,' 'advances,' and 'key factors' highlight participants' interest in the research’s contributions, though the tone remains somewhat reserved, focusing on sharing information rather than advocating for immediate change.
Most discussions show neutrality or mild support for the article, with some posts recognizing its insights without strong endorsement.
The social discussions demonstrate moderate curiosity, particularly among those interested in rheumatology and autoimmune conditions, but not overwhelmingly so.
Participants reference specific aspects like barriers and facilitators or biomarkers, indicating some depth, though the overall engagement remains moderate.
There is some acknowledgment of scientific progress, but the direct influence on clinical practice or policy remains less emphasized.
Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dysregulation ⏩Emerging treatments: Promising therapies ⏩Real-world impact: Anifrolumab and belimumab continue to prove effective https://t.co/tBA637jNZ7 https://t.co/7QQBNHKaBs
Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramuscular involvement ⏩ASSD often leads to severe lung disease; anti-PL7 worsens it. ⏩JAK inhibitors show promise in treatment. https://t.co/w74JNaQhPE https://t.co/m4mCO7zNYZ
SSc、one year in review 2025（Clin Exp Rheumatol 2025） ✅アニフロルマブ治験中 ✅シルデナフィル心保護、セレキシパグ末梢血管に有望 ✅造血幹細胞移植は予後改善もリスクあり ✅CAR-Tは有望治療 ✨日医大桑名先生の進行性SSc-ILD予測研究も取り上げられております。 https://t.co/xlfQyoq4PE
巨細胞性動脈炎（GCA）の疫学とリスク要因（Clin Exp Rheumatol 2025） ✅高齢女性に多く70〜80歳で発症ピーク ✅北欧系で高頻度 ✅HLA-DRB1*04等遺伝要因 ✅PMR合併、季節性やPM10曝露関与 https://t.co/RS8Q71dmb3 https://t.co/vbSaIanI4k
日本とブラジルのMDA5抗体陽性皮膚筋炎の臨床状の違い ・34人のブラジル人、65人の日本人 ・ILD：ブラジル（1/34）<日本（50%以上） https://t.co/Fvu9YyrFzP
The third 2025 issue is online https://t.co/ijT428tFLA with the One year in review on Systemic #Lupus Erythematosus https://t.co/ugJkwLtJHr https://t.co/2vcegsNxW0
Collagen is one of the most important proteins in the human body and is essential for maintaining skin firmness and joint health. This video analyzes the scientific evidence surrounding collagen supplements, their…
This video discusses the complex effects of cannabis, particularly its compounds like THC and CBD, on cardiovascular health. With the rising legalization and use among younger populations, understanding its health…
Struggling with knee osteoarthritis pain? You're not alone. This video presents three powerful, science-backed strategies to reduce pain, restore mobility, and protect your knees. Learn effective exercises and tips to…
RT @rheum_showa: SSc、one year in review 2025（Clin Exp Rheumatol 2025） ✅アニフロルマブ治験中 ✅シルデナフィル心保護、セレキシパグ末梢血管に有望 ✅造血幹細胞移植は予後改善もリスクあり ✅CAR-Tは有望治療…
RT @rheum_showa: SSc、one year in review 2025（Clin Exp Rheumatol 2025） ✅アニフロルマブ治験中 ✅シルデナフィル心保護、セレキシパグ末梢血管に有望 ✅造血幹細胞移植は予後改善もリスクあり ✅CAR-Tは有望治療…
RT @rheum_showa: SSc、one year in review 2025（Clin Exp Rheumatol 2025） ✅アニフロルマブ治験中 ✅シルデナフィル心保護、セレキシパグ末梢血管に有望 ✅造血幹細胞移植は予後改善もリスクあり ✅CAR-Tは有望治療…
SSc、one year in review 2025（Clin Exp Rheumatol 2025） ✅アニフロルマブ治験中 ✅シルデナフィル心保護、セレキシパグ末梢血管に有望 ✅造血幹細胞移植は予後改善もリスクあり ✅CAR-Tは有望治療 ✨日医大桑名先生の進行性SSc-ILD予測研究も取り上げられております。 https://t.co/xlfQyoq4PE
La foi en Dieu et l'optimisme sont de grandes forces pour contrecarrer la maladie et maintenir la sante https://t.co/80ktoOHEa7
RT @rheum_showa: 巨細胞性動脈炎（GCA）の疫学とリスク要因（Clin Exp Rheumatol 2025） ✅高齢女性に多く70〜80歳で発症ピーク ✅北欧系で高頻度 ✅HLA-DRB1*04等遺伝要因 ✅PMR合併、季節性やPM10曝露関与 https:/…
RT @rheum_showa: 巨細胞性動脈炎（GCA）の疫学とリスク要因（Clin Exp Rheumatol 2025） ✅高齢女性に多く70〜80歳で発症ピーク ✅北欧系で高頻度 ✅HLA-DRB1*04等遺伝要因 ✅PMR合併、季節性やPM10曝露関与 https:/…
RT @rheum_showa: 巨細胞性動脈炎（GCA）の疫学とリスク要因（Clin Exp Rheumatol 2025） ✅高齢女性に多く70〜80歳で発症ピーク ✅北欧系で高頻度 ✅HLA-DRB1*04等遺伝要因 ✅PMR合併、季節性やPM10曝露関与 https:/…
RT @rheum_showa: 巨細胞性動脈炎（GCA）の疫学とリスク要因（Clin Exp Rheumatol 2025） ✅高齢女性に多く70〜80歳で発症ピーク ✅北欧系で高頻度 ✅HLA-DRB1*04等遺伝要因 ✅PMR合併、季節性やPM10曝露関与 https:/…
巨細胞性動脈炎（GCA）の疫学とリスク要因（Clin Exp Rheumatol 2025） ✅高齢女性に多く70〜80歳で発症ピーク ✅北欧系で高頻度 ✅HLA-DRB1*04等遺伝要因 ✅PMR合併、季節性やPM10曝露関与 https://t.co/RS8Q71dmb3 https://t.co/vbSaIanI4k
El autor es el gastroenterólogo Enzo Grossi, miembro entre otros de la Università della Svizzera italiana, la fundación IBSA de investigación biomédica y la fundación “Villa Santa Maria”.
https://t.co/jbrq9kslK6
https://t.co/kIQqrXgXlp
https://t.co/Wi26DVPilM
RT @clinexprheum: New issue online Behçet's disease and other autoinflammatory conditions https://t.co/9M8x31uYd0 Free to view #Behçet's…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @clinexprheum: The third 2025 issue is online https://t.co/ijT428tFLA with the One year in review on Systemic #Lupus Erythematosus https…
RT @clinexprheum: The third 2025 issue is online https://t.co/ijT428tFLA with the One year in review on Systemic #Lupus Erythematosus https…
RT @clinexprheum:
RT @clinexprheum: The third 2025 issue is online https://t.co/ijT428tFLA with the One year in review on Systemic #Lupus Erythematosus https…
RT @clinexprheum: The third 2025 issue is online https://t.co/ijT428tFLA with the One year in review on Systemic #Lupus Erythematosus https…
RT @clinexprheum: The third 2025 issue is online https://t.co/ijT428tFLA with the One year in review on Systemic #Lupus Erythematosus https…
RT @clinexprheum: The third 2025 issue is online https://t.co/ijT428tFLA with the One year in review on Systemic #Lupus Erythematosus https…
RT @clinexprheum: The third 2025 issue is online https://t.co/ijT428tFLA with the One year in review on Systemic #Lupus Erythematosus https…
The third 2025 issue is online https://t.co/ijT428tFLA with the One year in review on Systemic #Lupus Erythematosus https://t.co/ugJkwLtJHr https://t.co/2vcegsNxW0
RT @sulaimanm2020: Pamidronate is effective and well tolerated in children with IBDs, especially when combined with other treatments. Clin…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
Pamidronate is effective and well tolerated in children with IBDs, especially when combined with other treatments. Clin Exp Rheumatol. 2025 March 20 doi: 10.55563/clinexprheumatol/y0ve3b. https://t.co/229KqLKGNi
RT @ZuccoNoel: Esta revisión destaca los avances clave en la investigación del lupus eritematoso sistémico (LES) durante 2024, abarcando la…
RT @ZuccoNoel: Esta revisión destaca los avances clave en la investigación del lupus eritematoso sistémico (LES) durante 2024, abarcando la…
RT @ZuccoNoel: Esta revisión destaca los avances clave en la investigación del lupus eritematoso sistémico (LES) durante 2024, abarcando la…
Esta revisión destaca los avances clave en la investigación del lupus eritematoso sistémico (LES) durante 2024, abarcando la patogénesis, nuevas terapias, biomarcadores y resultados clínicos. https://t.co/bjKVHOAwcP https://t.co/RRC7DHwFIJ
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
RT @autoinMI_tauli: Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dy…
Systemic lupus erythematosus: one year in review 2025 ⏩Breakthroughs in SLE research 2024: New insights into immune dysregulation ⏩Emerging treatments: Promising therapies ⏩Real-world impact: Anifrolumab and belimumab continue to prove effective https://t.co/tBA637jNZ7 https://t.co/7QQBNHKaBs
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
RT @autoinMI_tauli: Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramusc…
Idiopathic inflammatory myopathies: year in review 2024 ⏩New biomarkers (IFNλ3, EIF2AK2) affect prognosis ⏩Extramuscular involvement ⏩ASSD often leads to severe lung disease; anti-PL7 worsens it. ⏩JAK inhibitors show promise in treatment. https://t.co/w74JNaQhPE https://t.co/m4mCO7zNYZ
RT @HirokiIkai: 日本とブラジルのMDA5抗体陽性皮膚筋炎の臨床状の違い ・34人のブラジル人、65人の日本人 ・ILD：ブラジル（1/34）<日本（50%以上） https://t.co/Fvu9YyrFzP
RT @HirokiIkai: 日本とブラジルのMDA5抗体陽性皮膚筋炎の臨床状の違い ・34人のブラジル人、65人の日本人 ・ILD：ブラジル（1/34）<日本（50%以上） https://t.co/Fvu9YyrFzP
RT @HirokiIkai: 日本とブラジルのMDA5抗体陽性皮膚筋炎の臨床状の違い ・34人のブラジル人、65人の日本人 ・ILD：ブラジル（1/34）<日本（50%以上） https://t.co/Fvu9YyrFzP
日本とブラジルのMDA5抗体陽性皮膚筋炎の臨床状の違い ・34人のブラジル人、65人の日本人 ・ILD：ブラジル（1/34）<日本（50%以上） https://t.co/Fvu9YyrFzP
RT @DrOlivierBoyer: Editorial @clinexprheum on from the International #Myositis Society (iMyoS) https://t.co/K8gCtDuZ31 @TheMyositisAss…
RT @DrOlivierBoyer: Editorial @clinexprheum on from the International #Myositis Society (iMyoS) https://t.co/K8gCtDuZ31 @TheMyositisAss…
RT @DrOlivierBoyer: Editorial @clinexprheum on from the International #Myositis Society (iMyoS) https://t.co/K8gCtDuZ31 @TheMyositisAss…
RT @DrOlivierBoyer: Editorial @clinexprheum on from the International #Myositis Society (iMyoS) https://t.co/K8gCtDuZ31 @TheMyositisAss…
RT @DrOlivierBoyer: Editorial @clinexprheum on from the International #Myositis Society (iMyoS) https://t.co/K8gCtDuZ31 @TheMyositisAss…
Editorial @clinexprheum on from the International #Myositis Society (iMyoS) https://t.co/K8gCtDuZ31 @TheMyositisAssc @Telethon_France @CureIBM @UKMyositis @Myositis_India @eular_org @ACRheum
RT @ArmenYuri: Barriers and facilitators to treat-to-target in axial spondyloarthritis in clinical practice: a mixed methods study @Officia…
RT @ArmenYuri: Barriers and facilitators to treat-to-target in axial spondyloarthritis in clinical practice: a mixed methods study @Officia…
Barriers and facilitators to treat-to-target in axial spondyloarthritis in clinical practice: a mixed methods study @Official_ASAS @ArLARheumatolog @PanlarLeague @RheumAFLAR @QRS_Qatar @svreumatologia @GeorgievMD @OlenaZimba @BurhanFatihKoy1 https://t.co/kakBLL7uo6
RT @ArmenYuri: Barriers and facilitators to treat-to-target in axial spondyloarthritis in clinical practice: a mixed methods study @Jarosaw…
RT @ArmenYuri: Barriers and facilitators to treat-to-target in axial spondyloarthritis in clinical practice: a mixed methods study @Jarosaw…
RT @ArmenYuri: Barriers and facilitators to treat-to-target in axial spondyloarthritis in clinical practice: a mixed methods study @Jarosaw…
Barriers and facilitators to treat-to-target in axial spondyloarthritis in clinical practice: a mixed methods study @JarosawNowakow6 @ZofiaGula @OlenaZimba @AcerSevtap @Official_ASAS @SpArthritis @AxSpA_HU @eular_org @PanlarLeague https://t.co/zUuOh0jEdb
RT @UCAMIraras: HILO: Resumen del 2024 en Sindrome de #Sjogren. Clin Exp Rheumatol. 2024 Dec;42(12):2322-2335. doi: 10.55563/clinexprheumat…
RT @clinexprheum:
Monocyte distribution width as a novel biomarker for #AOSD: "Elevated MDW and its positive correlation with inflammatory parameters in AOSD patients indicate MDW as a novel activity indicator" ⬇️⬇️ https://t.co/OuNfPvE77R #autoinflammatory #stillsdisease
RT @narly_benachi: Estudio de #validación de una fórmula predictiva de #fibromialgia en sujetos con antecedente de dolor crónico. @fibrono…
RT @clinexprheum:
RT @clinexprheum:
Osteoporosis and gut microbiota, radiofrequency echographic multispectrometry and machine learning: one year in review... - Maffi M et al. - https://t.co/fgePGb5rj5 #microbiome
RT @microbe_article: Gut microbiome profiling in systemic sclerosis: a metagenomic approach. - Tan TC et al. - https://t.co/RKAA6fzD5D #mic…
RT @microbe_article: Gut microbiome profiling in systemic sclerosis: a metagenomic approach. - Tan TC et al. - https://t.co/RKAA6fzD5D #mic…
Gut microbiome profiling in systemic sclerosis: a metagenomic approach. - Tan TC et al. - https://t.co/RKAA6fzD5D #microbiome
The faecal microbiota is distinct in hla-b27+ ankylosing spondylitis patients versus hla-b27+ healthy controls. - Stoll ML et al. - https://t.co/3f41FzAVJC #microbiome
MF
PÜ